ArticleNeuro-oncology2016
68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Pooled it
- Correlation of [EJNMMI research · 2026Article
- High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Somatostatin receptor PET in meningioma: diagnosis, therapy, and surveillance.Nuclear medicine communications · 2026Review
- SUV-max ofJournal of neuro-oncology · 2025Article
- Synchronous multiple meningiomas and renal cell carcinoma metastasis to the brain in a 68Ga-DOTATATE scan: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.AJNR. American journal of neuroradiology · 2025Review
- Article
- DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas.AJNR. American journal of neuroradiology · 2024Observational
- Utility of 68Ga-DOTATATE PET-MRI for Gamma Knife® stereotactic radiosurgery treatment planning for meningioma.The British journal of radiology · 2024Article
- Combined transarterial and percutaneous preoperative embolization of transosseous meningioma.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2023Article
- Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.Journal of neuro-oncology · 2023Article
- Cost-Effectiveness Analysis ofAJNR. American journal of neuroradiology · 2023Article
- Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023Article
- Advances in PET imaging for meningioma patients.Neuro-oncology advances · 2023Article
- Meningioma grading based on positron emission tomography: A systematic review and meta-analysis.World neurosurgery: X · 2023Article
- The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- Efficacy and safety of peptide receptor radionuclide therapy with [European journal of nuclear medicine and molecular imaging · 2023Article
- Imaging Characteristics of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDOTATATE-based radionuclides have added new options in the diagnosis and treatment of meningiomas; however, a reliable predictor of tumor growth has still not been established.
methodsWe analyzed 64 meningiomas imaged with (68)Ga-DOTATATE PET. Tumor growth rates were calculated by volumetric analysis of sequential MRI scans. Maximums of standardized uptake values (SUVmax) were correlated with tumor growth and covariates.
resultsWorld Health Organization (WHO) grades I and II meningiomas showed a correlation of SUVmax and tumor growth rate (meningiomas limited to the intracranial compartment: r = 0.757, P < .001, and transosseous growing meningiomas: r = 0.819, P = .024). SUVmax was significantly higher and the slope of the linear regression significantly steeper in transosseous compared with intracranial meningiomas (both P < .001). The association remained significant in multivariate analysis, and the prediction of tumor growth rate was independent of WHO grade. Anaplastic meningiomas showed no significant correlation of SUVmax and tumor growth.
conclusions(68)Ga-DOTATATE PET is a reliable predictor of tumor growth in WHO grades I and II meningiomas and provides additional information to conventional cross-sectional imaging modalities. Hence, (68)Ga-DOTATATE PET can assist in selecting the time point for treatment initiation. Furthermore, meningiomas with fast tumor growth and transosseous expansion elicit the highest DOTATATE binding; therefore, they might be especially suited for DOTATATE-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.